Wenzhi Tian

This paper develops a small molecule, BRD8833, that induces BCR-ABL phosphorylation to disrupt its active site electric field, leading to loss of hyperactivity and apoptosis in BCR-ABL-dependent cancer cells.

This paper introduces an AMPK PHICS platform that enables controlled protein phosphorylation under physiological conditions, demonstrating its utility in regulating oncogenic signaling and phase separation.